Inventor · disambiguated record
Ashish Chatterji
Also filed as: CHATTERJI ASHISH
9 granted patents·18 pending applications·4 citations·filing 2007–2024
80Inventor score
Files withCHATTERJI ASHISH9HOFFMANN LA ROCHE7AMNEAL COMPLEX PRODUCTS RES LLC4KASHIV BIOSCIENCES LLC3KASHIV PHARMA LLC2
Top patents by PatentIndex Score
27 records- 0189US11318091B2Gastroretentive dosage forms for sustained drug deliveryAMNEAL COMPLEX PRODUCTS RES LLC·Filed 2021·Granted May 3, 2022·1 cites·20 claims
- 0287US11007145B2Gastroretentive dosage forms for sustained drug deliveryKASHIV SPECIALTY PHARMACEUTICALS LLC·Filed 2020·Granted May 18, 2021·1 cites·14 claims
- 0386US10918597B2Gastroretentive dosage forms for sustained drug deliveryKASHIV PHARMA LLC·Filed 2018·Granted Feb 16, 2021·1 cites·27 claims
- 0486US2025073216A1Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) AntagonistsHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 0586US2024335376A1Gastroretentive dosage forms for sustained drug deliveryAMNEAL COMPLEX PRODUCTS RES LLC·Filed 2024·Application pending·0 cites
- 0685US12042559B2Gastroretentive dosage forms for sustained drug deliveryAMNEAL COMPLEX PRODUCTS RES LLC·Filed 2023·Granted Jul 23, 2024·0 cites·20 claims
- 0785US10857098B2Gastroretentive dosage forms for sustained drug deliveryKASHIV BIOSCIENCES LLC·Filed 2020·Granted Dec 8, 2020·1 cites·14 claims
- 0880US2022218604A1Gastroretentive dosage forms for sustained drug deliveryAMNEAL COMPLEX PRODUCTS RES LLC·Filed 2022·Application pending·0 cites
- 0970US2022241260A9Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) AntagonistsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 1064US2015209294A1Pharmaceutical composition and processHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 1164US2019216789A1Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) AntagonistsHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 1260US2015140087A1Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) AntagonistsHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 1357US2007184113A1Pharmaceutical composition and processCHATTERJI ASHISH·Filed 2007·Application pending·0 cites
- 1456US10744131B2Abuse-resistant drug formulationsKASHIV BIOSCIENCES LLC·Filed 2014·Granted Aug 18, 2020·0 cites·20 claims
- 1556US2008293787A1Pharmaceutical compositions for poorly soluble drugsCHATTERJI ASHISH·Filed 2008·Application pending·0 cites
- 1656US2012129898A1Pharmaceutical compositions for poorly soluble drugsCHATTERJI ASHISH·Filed 2012·Application pending·0 cites
- 1755US2011245305A1Pharmaceutical compositions for poorly soluble drugsCHATTERJI ASHISH·Filed 2011·Application pending·0 cites
- 1855US2017202819A1Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonistsHOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 1953US2011028524A1Pharmaceutical compositions for poorly soluble drugsCHATTERJI ASHISH·Filed 2010·Application pending·0 cites
- 2047US2014128431A1Pharmaceutical composition with improved bioavailability, safety and tolerabilityHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 2146US10695296B2Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredientASANA BIOSCIENCES LLC·Filed 2018·Granted Jun 30, 2020·0 cites·28 claims
- 2246US2012039999A1Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonistsCHATTERJI ASHISH·Filed 2011·Application pending·0 cites
- 2341US10632113B2Abuse-resistant drug formulations with built-in overdose protectionKASHIV BIOSCIENCES LLC·Filed 2015·Granted Apr 28, 2020·0 cites·24 claims
- 2437US2018303757A1Enhanced abuse-deterrent formulations of oxycodoneKASHIV PHARMA LLC·Filed 2016·Application pending·0 cites
- 2535US8222230B2Pharmaceutical compositions with superior product performance and patient complianceCHATTERJI ASHISH·Filed 2010·Granted Jul 17, 2012·0 cites·21 claims
- 2633US2012213827A1Process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusionCHATTERJI ASHISH·Filed 2012·Application pending·0 cites
- 2727US2012040008A1Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonistsCHATTERJI ASHISH·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ashish Chatterji files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →